Novartis reported Phase 3 results showing its ganaplacide‑lumefantrine combination (GanLum) met the trial’s primary endpoint and achieved cure rates that meet World Health Organization thresholds. The multicountry study enrolled 1,688 adults and children across 34 sites in sub‑Saharan Africa and showed non‑inferiority to standard artemisinin‑based therapy, with one analysis reporting a 97% day‑28 cure rate. Novartis, developing GanLum with the Medicines for Malaria Venture, says the regimen retains activity against parasites with artemisinin resistance markers and reduces transmission potential. The company said it will pursue regulatory submissions promptly; the data position GanLum as the first novel antimalarial candidate in more than two decades to confront rising resistance.